Results 91 to 100 of about 10,985 (213)

From lipid biophysics to first-in human test: topical liposomal treatment for cutaneous leishmaniasis

Precision Nanomedicine
Cutaneous leishmaniasis (CL) remains a major neglected disease with limited therapeutic op-tions and expanding geographic distribution. To develop a safe, accessible local treatment, we formulated topical Miltefosine gels incorporating different types of
Dolores Catalina Carrer
doaj   +1 more source

Evaluation of In Vitro Cytotoxic and Apoptotic Effects of Miltefosine on the Toxoplasma gondii RH Strain

Iranian Journal of Parasitology
Background: We aimed to investigate the cytotoxic and apoptotic effects of miltefosine on Toxoplasma gondii RH strain by various techniques. Methods: The study was conducted at the Department of Parasitology and Mycology, Urmia University of Medical ...
Shahram Khademvatan, Elham Yousefi, Negar Asadi, Esmaeil Abasi   +3 more
doaj  

Miltefosine versus meglumine antimoniate in the treatment of mucosal leishmaniasis [PDF]

, 2014
El tratamiento convencional para la leishmaniasis tegumentaria es el antimoniato de meglumina, el cual presenta falla terapéutica creciente, producción de efectos adversos graves, y necesidad de administración parenteral, justificando la búsqueda de ...
Barrio, Alejandra, Basombrio, Miguel Angel Manuel, Beckar, Josefina, Garcia Bustos, Maria Fernanda, Moreno, Sonia, Parodi Ramoneda, Cecilia María   +5 more
core  

Clinical, histopathological and parasitological follow-up of dogs naturally infected by Leishmania infantum before and after miltefosine treatment and associated therapies.

PLoS ONE
In Brazil, Visceral Leishmaniases is caused by Leishmania infantum, and domestic dogs are the main reservoirs in its urban transmission cycle. As an alternative to euthanizing dogs, miltefosine has been used to treat canine visceral leishmaniasis since ...
Amábilli de Souza Rosar, Carolina Leite Martins, Álvaro Menin, Carolina Reck, Edmundo Carlos Grisard, Glauber Wagner, Mário Steindel, Patricia Hermes Stoco, Patricia Flavia Quaresma   +8 more
doaj   +1 more source

Clinical guidelines for the management of cutaneous leishmaniasis in British military personnel. [PDF]

, 2005
Bailey, MS, Beeching, NJ, Bryceson, AD, Chiodini, PL, Ellis, CJ, Green, AD, Lockwood, DN, O'Dempsey, TJ   +7 more
core   +1 more source

Unmasking the Mechanism behind Miltefosine: Revealing the Disruption of Intracellular Ca²⁺ Homeostasis as a Rational Therapeutic Target in Leishmaniasis and Chagas Disease

Biomolecules
Originally developed as a chemotherapeutic agent, miltefosine (hexadecylphosphocholine) is an inhibitor of phosphatidylcholine synthesis with proven antiparasitic effects.
Gustavo Benaim, Alberto Paniz-Mondolfi
doaj   +1 more source

Reworking the treatment of Indian Post kala-azar dermal leishmaniasis: A two-step therapy

Journal of Vector Borne Diseases
In the current scenario, treatment of Post kala-azar dermal leishmaniasis (PKDL) is intravenous liposomal amphotericin B or oral miltefosine. Over the years, there has been a gradual decline in the efficacy of miltefosine and a rise in permanent loss of ...
Sushruta Kathuria, Yugansh Gautam, Niti Khunger, Shruti Sharma, Ruchi Singh   +4 more
doaj   +1 more source

Concordant HIV Infection and Visceral Leishmaniasis in Ethiopia: The Influence of Antiretroviral Treatment and Other Factors on Outcome [PDF]

, 2008
Bogale, A, Collin, S, Davidson, R N, Ritmeijer, K, ter Horst, R   +4 more
core   +2 more sources

Miltefosine Drug Concerns [PDF]

Clinical Infectious Diseases, 2013
Subhash C, Arya, Nirmala, Agarwal
openaire   +2 more sources

Induction of Early Autophagic Process on Leishmania amazonensis by Synergistic Effect of Miltefosine and Innovative Semi-synthetic Thiosemicarbazone [PDF]

, 2017
Amanda L. Moreira, Benedito P. Dias-Filho, Celso V. Nakamura, Cleuza C. Silva, Débora B. Scariot, Elizandra A. Britta, Hugo Falzirolli, Tânia Ueda-Nakamura   +7 more
core   +1 more source